Summit Therapeutics stockholders elect all nine directors, approve 8M share increase at annual meeting

Summit Therapeutics Inc.

All nine director nominees elected with strong support; highest withheld votes were 25M for Kenneth A. Clark.
Ratification of PricewaterhouseCoopers as auditor passed: 677.3M for, 85K against.
Advisory vote on named executive officer compensation passed: 622.6M for, 24.4M against.
Plan amendment to increase authorized shares by 8M approved: 619.8M for, 27.2M against.
Annual meeting held June 10, 2026; all proposals approved as recommended by the Board.

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Summit Therapeutics Inc. shareholders approved Non-binding advisory vote to approve the compensation paid to the Company's named executive officers at the 2026-06-10 meeting.

Proposal: say on pay
Outcome: passed
Meeting: 2026-06-10

Exact text from the filing

Proposal 3 For Against Abstain Broker Non-Votes Non-binding advisory vote to approve the compensation of named executive officers 622,624,328 24,445,791 101,383 30,576,341

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Summit Therapeutics Inc. shareholders approved Election of nine directors to serve until the Company's 2027 Annual Meeting of Stockholders and until their successors are duly elected and qualified at the 2026-06-10 meeting.

Proposal: director election
Outcome: passed
Meeting: 2026-06-10

Exact text from the filing

Proposal 1 Election of Directors Director Nominees For Withheld Broker Non-Votes Robert W. Duggan 636,409,964 10,761,538 30,576,341 Mahkam Zanganeh 637,405,433 9,766,069 30,576,341 Manmeet Soni 636,690,652 10,480,850 30,576,341 Kenneth A. Clark 622,127,920 25,043,582 30,576,341 Robert Booth 646,257,923 913,579 30,576,341 Alessandra Cesano 646,263,718 907,784 30,576,341 Yu (Michelle) Xia 636,028,876 11,142,626 30,576,341 Mostafa Ronaghi 646,570,238 601,264 30,576,341 Jeff Huber 646,659,701 511,801 30,576,341

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Summit Therapeutics Inc. shareholders approved Ratification of the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 at the 2026-06-10 meeting.

Proposal: auditor ratification
Outcome: passed
Meeting: 2026-06-10

Exact text from the filing

Proposal 2 For Against Abstain Broker Non-Votes Ratification of the appointment of PricewaterhouseCoopers LLP for the fiscal year ending December 31, 2026 677,302,337 85,284 360,222 —

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Summit Therapeutics Inc. shareholders approved Approval of an amendment to the Summit Therapeutics Inc. 2020 Stock Incentive Plan to increase the number of shares of the Company's common stock issuable under the Plan by 8,000,000 shares at the 2026-06-10 meeting.

Proposal: equity plan
Outcome: passed
Meeting: 2026-06-10

Exact text from the filing

Proposal 4 For Against Abstain Broker Non-Votes Approval of an amendment to the Plan to increase the number of shares of the Company's common stock issuable under the Plan by 8,000,000 shares 619,799,393 27,247,910 124,199 30,576,341

View on SEC.gov

1639 shareholder votes filed in the last 30 days. Browse all shareholder votes →

Summit Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001599298-26-000054

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.